Avelit Pharma - Company finances
|
EUR
|
2024
From: 2024-02-19
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 93,809 | 267,740 |
| Profit before tax | 36,242 | 36,426 |
| Net profit | 30,797 | 30,233 |
| Equity | 31,797 | 4,383 |
| Liabilities | 22,027 | 33,754 |
| Non-current assets | 0 | 0 |
| Current assets | 53,824 | 38,137 |
| Total assets | 53,824 | 38,137 |
|
Taxes paid
|
||
| STI taxes | 5,523 | 30,904 |
|
Financial indicators
|
||
| Revenue change y/y | - | +185.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 57.2% | 79.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 96.9% | 689.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 32.8% | 11.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 38.6% | 13.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.7 | 7.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 93,809 | 267,740 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Avelit Pharma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-07-16 | 2024-07-28 | 2.77 |
Avelit Pharma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Avelit Pharma, UAB (code 306679358) is a Private Limited Liability Company engaged in the wholesale of other food products. In 2025, the company generated revenue of €267.7K, up 185.4% year on year from €93.8K in 2024. Net profit was €30.2K in 2025, broadly in line with €30.8K a year earlier, while profit before tax remained stable at €36.4K versus €36.2K in 2024. As revenue rose faster than profit, the net profit margin narrowed to 11.3% from 32.8% in 2024. The balance sheet weakened over the year: total assets decreased to €38.1K from €53.8K, equity fell to €4.4K from €31.8K, and liabilities increased to €33.8K from €22.0K. The company’s equity base is very small relative to liabilities, which makes return measures unusually elevated. Asset turnover reached 7.02x, indicating strong revenue generation relative to the asset base. Revenue per employee stood at €267.7K in 2025.